251 related articles for article (PubMed ID: 10188888)
1. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
2. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer.
Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P
Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646
[TBL] [Abstract][Full Text] [Related]
3. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
Nicolini A; Carpi A; Ferrari P; Pieri L
Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
[TBL] [Abstract][Full Text] [Related]
4. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
9. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
10. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
[TBL] [Abstract][Full Text] [Related]
11. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
12. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients.
Nicolini A; Carpi A; Di Marco G; Giuliani L; Giordani R; Palla S
Cancer; 1989 May; 63(10):2037-46. PubMed ID: 2702573
[TBL] [Abstract][Full Text] [Related]
13. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?
Buffaz PD; Gauchez AS; Caravel JP; Vuillez JP; Cura C; Agnius-Delord C; Fagret D
Eur J Nucl Med; 1999 Jan; 26(1):8-11. PubMed ID: 9933655
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
15. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
16. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
17. The Role of TPS and TPA in the Diagnostics of Distant Metastases.
Kucera R; Topolcan O; Fiala O; Kinkorova J; Treska V; Zedníková I; Slouka D; Simanek V; Safanda M; Babuska V
Anticancer Res; 2016 Feb; 36(2):773-7. PubMed ID: 26851038
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
[TBL] [Abstract][Full Text] [Related]
20. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
Yildiz M; Oral B; Bozkurt M; Cobaner A
Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]